NYCHBL co-founder and Context Matters CEO Dr. Yin Ho published a thought-provoking article in PharmaPhorum on the recent controversy surrounding the high price of Gilead’s Hepatitis C drug: Sovaldi and the politics of high-priced drugs: are we asking the right questions?
Miracle drug or budget disaster?
Sovaldi, has been widely praised as a significant breakthrough and an important innovation. It offers a cure rate of around 90 per cent and, for some patients, comes with far milder side effects than peginterferon-based regimens. And Gilead appears to be reaping the benefits, with sales of approximately $5.8 billion in the first two quarters of 2014. In its first year, it is on track to become one of the best-selling drugs ever.or the U.S. health care delivery system. Continue reading here.